PTO- 1478 |
Approved for use through 10/31/2024. OMB 0651-0009 |
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number |
Serial Number: 97384728 |
Filing Date: 04/27/2022 |
Input Field |
Entered |
SERIAL NUMBER | 97384728 |
---|---|
MARK INFORMATION | |
*MARK | \\TICRS\EXPORT18\IMAGEOUT 18\973\847\97384728\xml1 \ APP0002.JPG |
SPECIAL FORM | YES |
USPTO-GENERATED IMAGE | NO |
LITERAL ELEMENT | GORDIAN |
COLOR MARK | NO |
*DESCRIPTION OF THE MARK (and Color Location, if applicable) |
The mark consists of the word Gordian with a stylized letter "o". |
PIXEL COUNT ACCEPTABLE | NO |
PIXEL COUNT | 487 x 103 |
REGISTER | Principal |
APPLICANT INFORMATION | |
*OWNER OF MARK | Gordian Biotechnology |
*MAILING ADDRESS | 953 Indiana Street |
*CITY | San Francisco |
*STATE (Required for U.S. applicants) |
California |
*COUNTRY/REGION/JURISDICTION/U.S. TERRITORY | United States |
*ZIP/POSTAL CODE (Required for U.S. and certain international addresses) |
94107 |
*EMAIL ADDRESS | XXXX |
LEGAL ENTITY INFORMATION | |
TYPE | corporation |
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY OF INCORPORATION | Delaware |
GOODS AND/OR SERVICES AND BASIS INFORMATION | |
INTERNATIONAL CLASS | 005 |
*IDENTIFICATION | Pharmaceutical preparations, biological preparations, and cell- and gene-based therapy products to prevent and treat age-related diseases, disorders, and conditions; pharmaceutical preparations, biological preparations, and cell- and gene-based therapy products to prevent and treat complex multigenic diseases, disorders, and conditions |
FILING BASIS | SECTION 1(b) |
INTERNATIONAL CLASS | 042 |
*IDENTIFICATION | Pharmaceutical and biological drug research and development services; cell- and gene-based therapy research and development services |
FILING BASIS | SECTION 1(b) |
INTERNATIONAL CLASS | 044 |
*IDENTIFICATION | Providing information on aging and complex multigenic diseases; providing information on research on aging and complex multigenic diseases; providing information on pharmaceutical drug, biological drug, and cell- and gene-based therapy research and development; providing information on computational biology, machine learning, and bioinformatics |
FILING BASIS | SECTION 1(b) |
ATTORNEY INFORMATION | |
NAME | Tracy-Gene G. Durkin |
ATTORNEY BAR MEMBERSHIP NUMBER | XXX |
YEAR OF ADMISSION | XXXX |
U.S. STATE/ COMMONWEALTH/ TERRITORY | XX |
FIRM NAME | Sterne, Kessler, Goldstein & Fox P.L.L.C. |
STREET | 1100 New York Avenue, N.W. |
CITY | Washington |
STATE | District of Columbia |
COUNTRY/REGION/JURISDICTION/U.S. TERRITORY | United States |
ZIP/POSTAL CODE | 20005 |
PHONE | 202-371-2600 |
FAX | 202-371-2540 |
EMAIL ADDRESS | tm@sternekessler.com |
OTHER APPOINTED ATTORNEY | Monica Riva Talley, Dana N. Justus, Ivy Clarice Estoesta, Lauriel F. Dalier, Shana L. Olson |
CORRESPONDENCE INFORMATION | |
NAME | Tracy-Gene G. Durkin |
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE | tm@sternekessler.com |
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) | tdurkin@sternekessler.com; jshirk@sternekessler.com; amartins@sternekessler.com |
FEE INFORMATION | |
APPLICATION FILING OPTION | TEAS Standard |
NUMBER OF CLASSES | 3 |
APPLICATION FOR REGISTRATION PER CLASS | 350 |
*TOTAL FEES DUE | 1050 |
*TOTAL FEES PAID | 1050 |
SIGNATURE INFORMATION | |
SIGNATURE | /Tracy Durkin/ |
SIGNATORY'S NAME | Tracy-Gene G. Durkin |
SIGNATORY'S POSITION | Attorney of Record, Washington, DC Bar Member |
SIGNATORY'S PHONE NUMBER | 202-371-2600 |
DATE SIGNED | 04/27/2022 |
SIGNATURE METHOD | Sent to third party for signature |
PTO- 1478 |
Approved for use through 10/31/2024. OMB 0651-0009 |
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number |
Serial Number: 97384728 |
Filing Date: 04/27/2022 |
The applicant's current Correspondence Information: |
Tracy-Gene G. Durkin |
PRIMARY EMAIL FOR CORRESPONDENCE: tm@sternekessler.com SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): tdurkin@sternekessler.com; jshirk@sternekessler.com; amartins@sternekessler.com Requirement for Email and Electronic Filing: I understand that a valid email address must be maintained by the applicant owner/holder and the applicant owner's/holder's attorney, if appointed, and that all official trademark correspondence must be submitted via the Trademark Electronic Application System (TEAS). |
|
|